verdinexor has been researched along with Osteosarcoma* in 1 studies
1 other study(ies) available for verdinexor and Osteosarcoma
| Article | Year |
|---|---|
The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.
Verdinexor (KPT-335) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) compound that inhibits the function of the nuclear export protein Exportin 1 (XPO1/CRM1). In the present study, we sought to characterize the expression of XPO1 in primary canine osteosarcoma (OS) tumour samples, OS cell lines and normal osteoblasts and evaluate the in vitro activity of verdinexor alone or in combination with doxorubicin. Canine OS cell lines and a subset of primary OS tumours showed increased XPO1 transcript and protein expression as compared with normal canine osteoblast cells. All canine OS cell lines exhibited dose-dependent growth inhibition and increased caspase 3,7 activity in response to low nanomolar concentrations of verdinexor (IC Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Biological Products; Cell Line, Tumor; Dog Diseases; Dogs; Doxorubicin; Hydrazines; Osteosarcoma | 2021 |